Cancer Molecular Markers
Advancing Personalized Medicine
Day 1 | Day 2 | Day 3
Friday, February 15
8:00 am Morning Coffee
8:30 Chairperson’s Remarks
Rob Mohney, Ph.D., Director, Projects (North American Pharma-Biotech), Metabolon, Inc.
8:35 Epigenetically Modified Highly Methylated Coding and Non-Coding RNA Promoter CpG Islands as Early Diagnostics Markers for Human Melanomas
Ranjan Perera, Ph.D., Associate Professor and Scientific Director, Analytical Genomics and Bioinformatics, Metabolic Signaling & Disease, Sanford-Burnham Medical Research Institute
Identification of previously uncharacterized methylated CpG islands in the regulatory regions as well as gene bodies of coding and non-coding genes in melanoma genome opens the possibility of using this extensive genome-wide epigenetic information for future melanoma stratification in patients.
9:05 NGS of Immune Repertoire for Cancer Biomarker Discovery
Jian Han, M.D., Ph.D., Faculty Investigator, HudsonAlpha Institute for Biotechnology, Director, R10K Project
We have developed a inclusive and semi-quantitative multiplex PCR method to amplify immune repertoire from a sample. A free online software package is developed to aid CDR3 analyses that featuring a dynamic error removal filter. The repertoire sequencing library can be generated automatically with iCubate instrument. We have launched an international collaboration project called R10K (R10K.org), aimed at sequencing 10,000 samples and study 100 diseases for biomarker discoveries.
9:35 Mutation Detection in Plasma Tumor DNA
Andrea L. Richardson, M.D., Ph.D., Associate Professor, Pathology, Harvard Medical School; Department of Cancer Biology, Dana-Farber Cancer Institute; Senior Staff Pathologist, Brigham and Women’s Hospital, Department of Pathology
The presentation will describe the BEAMING technology for mutation detection from free tumor DNA in plasma, present data from published studies on the specificity and sensitivity of the method, describe the potential applications of the technology to clinical management, and discuss the limitations of the method.
10:05 Sponsored Presentations (Opportunities Available)
10:35 Coffee Break
11:00 Clonal Analysis and Molecular Profiling for Patient Selection
Michael Barrett, Ph.D., Associate Professor, Clinical Translational Research Division; Unit Head, Oncogenomics Laboratory, TGEN
Cancers frequently arise as a result of an acquired genomic instability and the subsequent evolution of neoplastic cells with variable genomes. Thus the behaviors of distinct clonal populations in each patient’s tumor underlie the clinical phenotypes of many cancers.
11:30 Molecular Profiling for Patient Selection: MD Anderson Perspective
Apostolia-Maria Tsimberidou, M.D., Ph.D., Associate Professor, Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center
12:00 pm Challenges and Issues in the Clinical Execution of a Biomarker Driven Clinical Trial
Jonathan Cheng, M.D., Director, Oncology Clinical Development, Merck
12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
1:45 PANEL DISCUSSION: Companion Diagnostics Post-Approval: Communicating Information to the Patient in a Global Environment
Remaining challenges of selling and marketing a companion diagnostic in the global marketplace and communicating information to the patient.
Moderator: Glenn A. Miller, Ph.D., Vice President and Head, Personalized Healthcare and Biomarkers, Strategy, Portfolio and Alliances, AstraZeneca Pharmaceuticals LP
Panelists: Richard E. Buller, M.D., Ph.D., Vice President, Translational Oncology, Pfizer, La Jolla
Walter H. Koch, Ph.D., Vice President and Head, Global Research, Roche Molecular Diagnostics
William Pignato, Global Head, Regulatory Affairs, Novartis Institutes for BioMedical Research, Inc.
3:20 Close of Conference
Day 1 | Day 2 | Day 3